ACP
ADVM

Acuta Capital Partners’s Adverum Biotechnologies ADVM Stock Holding History

Acuta Capital Partners’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,000
Closed -$1.15M – 33
2019
Q4 		$1.15M Buy
+10,000
New +$881K 0.29% 36

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Acuta Capital Partners's ADVM Position: Q3 2020 in Review

Acuta Capital Partners sold out of Adverum Biotechnologies (ADVM) in Q3 2020, closing a stake of 174,650 shares — an estimated $36.5M sold.

Acuta Capital Partners first reported a position in ADVM in Q1 2019 and held it in 5 quarters. The position peaked at $36.5M in Q2 2020. 160 funds tracked by Wall St. Rank hold ADVM as of Q3 2020.

  • Acuta Capital Partners reported no remaining Adverum Biotechnologies position as of Q3 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 174,650 Adverum Biotechnologies shares in Q3 2020, an estimated $36.5M.
  • Acuta Capital Partners first reported a position in Adverum Biotechnologies in Q1 2019 and held it in 5 quarters.
  • Acuta Capital Partners's Adverum Biotechnologies position peaked at $36.5M in Q2 2020.
  • 160 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2020.

Based on Acuta Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.